Drug Safety Cmte. To Review Accutane iPLEDGE Program
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Drug Safety & Risk Management Advisory Committee may discuss measures to evaluate the revised risk management program during its Feb. 10 meeting.